{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:35:26Z","timestamp":1792740926860,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.08.017","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T09:18:10Z","timestamp":1597137490000},"page":"6381-6387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-4450","authenticated-orcid":false,"given":"Christine","family":"Grady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Wendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Rid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.08.017_b0005","unstructured":"Johns Hopkins University, Coronavirus Resource Center. Available at https:\/\/coronavirus.jhu.edu\/map.html [accessed August 2, 2020]."},{"key":"10.1016\/j.vaccine.2020.08.017_b0010","unstructured":"Draulans D. Finally, a virus got me. Scientist who fought Ebola and HIV reflects on facing death from COVID-19. Sci Mag [May 8, 2020]."},{"key":"10.1016\/j.vaccine.2020.08.017_b0015","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0020.1","doi-asserted-by":"crossref","unstructured":"(a) Cohen J. U.S. \"Warp Speed\" vaccine effort comes out of the shadows. Science 2020","DOI":"10.1126\/science.368.6492.692"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0020.2","unstructured":"(b) Department of Health and Human Services, HHS Fact Sheet: Operation Warp Speed. June 16, 2020. https:\/\/www.hhs.gov\/about\/news\/2020\/06\/16\/fact-sheet-explaining-operation-warp-speed.html."},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0020.3","doi-asserted-by":"crossref","unstructured":"(a) Cohen J. U.S. \"Warp Speed\" vaccine effort comes out of the shadows. Science 2020; 368(6492): 692-693;","DOI":"10.1126\/science.368.6492.692"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0020.4","unstructured":"(b) Department of Health and Human Services, HHS Fact Sheet: Operation Warp Speed. June 16, 2020. https:\/\/www.hhs.gov\/about\/news\/2020\/06\/16\/fact-sheet-explaining-operation-warp-speed.html."},{"key":"10.1016\/j.vaccine.2020.08.017_b0025","unstructured":"Gates B. What you need to know about the COVID-19 vaccine. GatesNotes, April 30, 2020. Available at https:\/\/www.gatesnotes.com\/Health\/What-you-need-to-know-about-the-COVID-19-vaccine."},{"key":"10.1016\/j.vaccine.2020.08.017_b0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.017_b0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The challenges of vaccine development against a new virus during a pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2020.08.017_b0040","doi-asserted-by":"crossref","unstructured":"(a) Kieny MP, Salama P. WHO R&D Blueprint: A global coordination mechanism for R&D preparedness. Lancet 2017; 389(10088):2469\u201370. doi: 10.1016\/S0140-6736(17)31635-5. (b) Platform for European preparedness against (re)emerging epidemics. https:\/\/www.prepare-europe.eu\/.","DOI":"10.1016\/S0140-6736(17)31635-5"},{"key":"10.1016\/j.vaccine.2020.08.017_b0045","doi-asserted-by":"crossref","unstructured":"(a) Bioworld, Biopharma products in development for COVID-19 Available at https:\/\/www.bioworld.com\/COVID19products#vac; (b) Thanh Le T, Andreadakis Z, Kumar A, G\u00f3mez Rom\u00e1n R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape Nature Reviews: Drug Discovery 2020; 19: 305\u20136.","DOI":"10.1038\/d41573-020-00073-5"},{"issue":"6497","key":"10.1016\/j.vaccine.2020.08.017_b0050","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.368.6497.1295","article-title":"Pandemic vaccines are about to face the real test","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0055.1","unstructured":"(a) World Health Organization. Access to COVID-19 Tools (ACT) Accelerator; 2020. https:\/\/www.who.int\/who-documents-detail\/access-to-covid-19-tools-(act)-accelerator."},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0055.2","doi-asserted-by":"crossref","unstructured":"(b) Cohen J. With record-setting speed, vaccine makers take their first shots at the new coronavirus. Science; 2020. doi: 10.1126\/science.abb9996.","DOI":"10.1126\/science.abb9996"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0060.1","unstructured":"2020. Available at https:\/\/www.hhs.gov\/about\/news\/2020\/03\/30\/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html [accessed July 10, 2020]. (b) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19: guidance for industry"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0060.2","unstructured":"June 2020. Available at https:\/\/www.fda.gov\/media\/139638\/download."},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0060.3","unstructured":"(a) U.S. Department of Health and Human Services. HHS accelerates clinical trials, prepares for manufacturing of COVID-19 vaccines; 2020. Available at https:\/\/www.hhs.gov\/about\/news\/2020\/03\/30\/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html [accessed July 10, 2020]."},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0060.4","unstructured":"(b) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19: guidance for industry; June 2020. Available at https:\/\/www.fda.gov\/media\/139638\/download."},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.017_b0065","doi-asserted-by":"crossref","first-page":"e1002632","DOI":"10.1371\/journal.pmed.1002632","article-title":"Choices in vaccine trial design in epidemics of emerging infections","volume":"15","author":"Kahn","year":"2018","journal-title":"PLoS Med"},{"issue":"6493","key":"10.1016\/j.vaccine.2020.08.017_b0070","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1126\/science.abc1076","article-title":"Ethics of controlled human infection to address COVID-19","volume":"368","author":"Shah","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.017_b0075","doi-asserted-by":"crossref","unstructured":"(a) World Health Organization. An international randomised trial of candidate vaccines against COVID-19; 28 May 2020. Available at https:\/\/www.who.int\/publications-detail\/an-international-randomised-trial-of-candidate-vaccines-against-covid-19 [accessed July 12, 2020]. (b) Angus DC, Alexander BM, Berry S. et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019; 18: 797\u2013807. https:\/\/doi.org\/10.1038\/s41573-019-0034-3. https:\/\/www.nature.com\/articles\/s41573-019-0034-3.","DOI":"10.1038\/s41573-019-0034-3"},{"key":"10.1016\/j.vaccine.2020.08.017_b0080","unstructured":"(a) Karlin-Smith S. COVID-19 vaccines: Ex-FDA leaders urge high bar for emergency use authorization. Available at https:\/\/pharmaintelligence.informa.com\/resources\/product-content\/covid-19-vaccines-ex-fda-leaders-urge-high-bar-for-emergency-use-authorization; (b) https:\/\/www.jnj.com\/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use."},{"key":"10.1016\/j.vaccine.2020.08.017_b0085","doi-asserted-by":"crossref","unstructured":"(a) Corey L, Mascola JR, Fauci AS, Collins FS. A Strategic Approach to COVID-19 Vaccine R & D. Science 2020; 368(6494): 948\u201350. DOI: 10.1126\/science.abc5312; (b) NIH, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). Available at https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ [accessed June 30, 2020].","DOI":"10.1126\/science.abc5312"},{"key":"10.1016\/j.vaccine.2020.08.017_b0090","doi-asserted-by":"crossref","unstructured":"Trogen B, Oshinsky D, Caplan A. Adverse consequences of rushing a SARS Co-V2 Vaccine. JAMA on line May 26, 2020","DOI":"10.1001\/jama.2020.8917"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.017_b0095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ni0504-465","article-title":"Ethics of vaccine research","volume":"5","author":"Grady","year":"2004","journal-title":"Nat Immunol"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0100.1","doi-asserted-by":"crossref","unstructured":"(a) Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME (2013) risk in vaccine research and development quantified. PLoS ONE, 2013. 8(3): e57755. https:\/\/doi.org\/10.1371\/journal.pone.0057755.","DOI":"10.1371\/journal.pone.0057755"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0100.2","doi-asserted-by":"crossref","unstructured":"(b) Heaton P. The COVID-19 vaccine multiverse. New Eng J Med July 14, 2020. DOI: 10.1056\/NEJMe2025111.","DOI":"10.1056\/NEJMe2025111"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.017_h0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.017_h0110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cpt.1627","article-title":"Development times and approval success rates for drugs to treat infectious diseases","volume":"107","author":"DiMasi","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.017_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/vim.2017.0126","article-title":"Vaccines we need but don\u2019t have","volume":"31","author":"Plotkin","year":"2018","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2020.08.017_b0115","doi-asserted-by":"crossref","unstructured":"Plotkin SL, Plotkin SA. A short history of vaccination. Chapter 1 in Stanley Plotkin, Walter Orenstein, Paul Offit, Kathryn Edwards (Eds.). Plotkin\u2019s Vaccines. NY: Elsevier, 2018. p. 1\u201315.","DOI":"10.1016\/B978-0-323-35761-6.00001-8"},{"key":"10.1016\/j.vaccine.2020.08.017_b0120","series-title":"The epidemic that never was: policy-making and the swine flu scare","author":"Neustadt","year":"1983"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.017_b0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test of concept studies investigating the efficacy of MRK ad5 gag\/pol\/nef sub-type B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"10.1016\/j.vaccine.2020.08.017_b0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jpids\/piy140","article-title":"Vaccine a double-edged sword","volume":"9","author":"Dengue","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2020.08.017_b0135","doi-asserted-by":"crossref","unstructured":"Destefano F, Offit P, Fisher A. Vaccine safety. Chapter 82 in Stanley Plotkin, Walter Orenstein, Paul Offit, Kathryn Edwards (Eds). Plotkin\u2019s Vaccines. NY: Elsevier, 2018. p. 1584\u2013600.","DOI":"10.1016\/B978-0-323-35761-6.00082-1"},{"key":"10.1016\/j.vaccine.2020.08.017_b0140","doi-asserted-by":"crossref","unstructured":"(a) World Health Organization. Report of the SAGE working group on vaccine hesitancy; 2014. Available at https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/october\/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf. (b) Larson HJ, Jarrett C , Eckersberger E , Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007\u20132012. Vaccine 2014; 32(19): 2150\u20139. https:\/\/doi.10.1016\/j.vaccine.2014.01.081.","DOI":"10.1016\/j.vaccine.2014.01.081"},{"key":"10.1016\/j.vaccine.2020.08.017_b0145","unstructured":"(a) Lipsitch M, Eyal N. Improving vaccine trials in infectious disease emergencies. Science 2017; 6347: 153\u20136.357. DOI: https:\/\/doi.10.1126\/science.aam833; (b) Edwards K, Kochhar S. Ethics of conducting clinical research in an outbreak setting. Annu Rev Virol 2020; 7:3.1\u20133.20. https:\/\/doi.org\/10.1146\/annurev-virology-013120013123; (c) Natl Acad Sci Eng Med 2017. Integrating clinical research into epidemic response: the Ebola experience. Washington, DC: Natl. Acad. Press. Available at https:\/\/www.nap.edu\/catalog\/24739\/integrating-clinical-research-into-epidemic-response-the-ebola-experience. (d) Nuffield Council on Bioethics. Research in Global Health Emergencies; 2020. Available at https:\/\/www.nuffieldbioethics.org\/publications\/research-in-global-health-emergencies\/read-the-short-report\/emergency-preparedness-response-and-research. (e) Kahn R, Rid A, Smith PG, Eyal N, Lipsitch M. Choices in vaccine trial design in epidemics of emerging infections. PLoS Med 2018; 15(8): e1002632. https:\/\/doi.org\/10.1371\/journal. pmed.1002632."},{"key":"10.1016\/j.vaccine.2020.08.017_b0150","series-title":"The Oxford textbook of clinical research ethics","article-title":"An ethical framework for biomedical research","author":"Emanuel","year":"2008"},{"issue":"6490","key":"10.1016\/j.vaccine.2020.08.017_b0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abc1731","article-title":"Against pandemic research exceptionalism","volume":"368","author":"London","year":"2020","journal-title":"Science"},{"issue":"6491","key":"10.1016\/j.vaccine.2020.08.017_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.abc5798","article-title":"Combination prevention for COVID-19","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"issue":"6494","key":"10.1016\/j.vaccine.2020.08.017_b0165","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0170.1","unstructured":"(a) Walsh B. The viral spread of anti-vaccination sentiment; 2020. Available at https:\/\/www.axios.com\/vaccine-coronavirus-pandemic-protest-b0ae67a4-1a12-4904-aec1-9cbc612ff8a0.html."},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0170.2","unstructured":"(b) Jamison P. Anti-vaccination leaders fuel black mistrust of medical establishment as covid-19 kills people of color. Washington Post; July 17, 2020. Available at: https:\/\/www.washingtonpost.com\/dc-md-va\/2020\/07\/17\/black-anti-vaccine-coronavirus-tuskegee-syphilis\/ [accessed July 17, 2020]."},{"key":"10.1016\/j.vaccine.2020.08.017_b0175","unstructured":"CNBC Why this former Harvard Med prof says Moderna's vaccine trial is 'publication by press release; May 20, 2020. Available at https:\/\/www.youtube.com\/watch?v=Nz_D_t6kcPs [accessed July 10, 2020]."},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.017_b0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.017_b0185","unstructured":"WorldoMeter. Brazil; 2020. https:\/\/www.worldometers.info\/coronavirus\/country\/brazil\/ [accessed August 2, 2020]."},{"issue":"3","key":"10.1016\/j.vaccine.2020.08.017_b0190","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2105\/AJPH.2015.302996","article-title":"Ethical rationale for the Ebola \u201cRing Vaccination\u201d trial design","volume":"106","author":"Rid","year":"2016","journal-title":"Am J Public Health."},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.017_b0195","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/infdis\/jiaa152","article-title":"Human challenge studies to accelerate coronavirus vaccine licensure","volume":"221","author":"Eyal","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.08.017_h0205","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.017_h0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s13104-018-3636-7","article-title":"The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process","volume":"11","author":"Catchpole","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2020.08.017_b0205","doi-asserted-by":"crossref","unstructured":"Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating development of SARS-CoV-2 vaccines \u2013 The role for controlled human infection models. N Engl J Med 2020. doi: 10.1056\/NEJMp2020076 [online ahead of print].","DOI":"10.1056\/NEJMp2020076"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.1","doi-asserted-by":"crossref","unstructured":"(a) Jarret C, Wilson R, O'Leary M, Eckersberger E, Larson H, SAGE working group on vaccine hesitancy. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015","DOI":"10.1016\/j.vaccine.2015.04.040"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.2","doi-asserted-by":"crossref","unstructured":"(c) Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R's) BMC Public Health 2019","DOI":"10.21203\/rs.2.11273\/v4"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.3","doi-asserted-by":"crossref","unstructured":"19: 1665. https:\/\/doi.org\/10.1186\/s12889-019-7978-4","DOI":"10.1186\/s12889-019-7978-4"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.4","doi-asserted-by":"crossref","unstructured":"(a) Jarret C, Wilson R, O'Leary M, Eckersberger E, Larson H, SAGE working group on vaccine hesitancy. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015; 33 (34): 4180-90.","DOI":"10.1016\/j.vaccine.2015.04.040"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.5","unstructured":"(b) World Health Organization. Key criteria for the ethical acceptability of COVID-19 human challenge studies; 2020. Available at https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331976\/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1;"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.6","doi-asserted-by":"crossref","unstructured":"(c) Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R's) BMC Public Health 2019; 19: 1665. https:\/\/doi.org\/10.1186\/s12889-019-7978-4;","DOI":"10.1186\/s12889-019-7978-4"},{"key":"#cr-split#-10.1016\/j.vaccine.2020.08.017_b0210.7","unstructured":"(d) Schoch-Spana M, Brunson E, Long R, Ravi S, Ruth A, Trotochaud M on behalf of the working group on readying populations for COVID-19 Vaccine. The public's role in COVID-19 vaccination: planning recommendations informed by design thinking and the social, behavioral, and communication sciences; 2020. The Johns Hopkins Center for Health Security. https:\/\/www.centerforhealthsecurity.org\/our-work\/publications\/the-publics-role-in-covid-19-vaccination."},{"key":"10.1016\/j.vaccine.2020.08.017_b0215","unstructured":"Morefield H. The potential risk of chasing a covid-19 vaccine. Washington Post; May 19, 2020. Available at https:\/\/www.washingtonpost.com\/outlook\/2020\/05\/19\/potential-risk-chasing-covid-19-vaccine\/."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:54Z","timestamp":1759401954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20310483"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}